Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7454285 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| Ammonia Solution, Strong SCHEMBL27641252 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL12934595 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL31174998 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL24449643 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL17976467 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL19222207 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL21742069 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL21742282 | 0.78 | CHRM2 (0.46) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL24380350 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1AHRCHRM2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3611164-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019135604-A1 | METHOD FOR PRODUCING LACTAM COMPOUND, AND LACTAM COMPOUND PRODUCED THEREBY | 기초과학연구원 | 2019-07-11 | — | — | WO | disclosed |
| WO-2019135600-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | 기초과학연구원 | 2019-07-11 | — | — | WO | disclosed |
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| US-7247761-B2 | Method for the production of aryl-aryl coupled compounds | MERCK PATENT GMBH (DE) | 2007-07-24 | — | — | US | disclosed |
| EP-1537161-B1 | METHOD FOR THE PRODUCTION OF ARYL-ARYL COUPLED COMPOUNDS | COVION ORGANIC SEMICONDUCTORS (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20060058524-A1 | Method for the production of aryl-aryl coupled compounds | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2006-03-16 | — | — | US | disclosed |
| EP-1537161-A1 | METHOD FOR THE PRODUCTION OF ARYL-ARYL COUPLED COMPOUNDS | Covion Organic Semiconductors GmbH (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022626-A1 | METHOD FOR THE PRODUCTION OF ARYL-ARYL COUPLED COMPOUNDS | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058524-A1 | Method for the production of aryl-aryl coupled compounds | TYR, AHR, ARSA | SMN1; SMN2 3909/4885L3MBTL1 3595/4885AHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.